William Blair analyst Sami Corwin maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today. The company’s shares closed today at $26.66.
According to TipRanks, Corwin is a 4-star analyst with an average return of 17.1% and a 53.57% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Bluebird Bio, PTC Therapeutics, and Beam Therapeutics.
PTC Therapeutics has an analyst consensus of Hold, with a price target consensus of $28.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on PTC Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $196.58 million and a GAAP net loss of $132.97 million. In comparison, last year the company earned a revenue of $217.13 million and had a GAAP net loss of $109.32 million
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics (PTCT) Company Description:
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Read More on PTCT:
- Citi opens ‘negative catalyst watch’ on PTC Therapeutics into EU decision
- PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
- PTC Therapeutics sees FY24 revenue $600M-$850M, consensus $652.89M
- PTC Therapeutics announces 2024 potential key clinical, regulatory events
- PTC Therapeutics sees FY23 revenue about $946M, consensus $936.85M
